Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT05511766
PHASE2/PHASE3

Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis

Sponsor: Tanta University

View on ClinicalTrials.gov

Summary

The study aims to compare the potential benefit of allopurinol versus atorvastatin in reducing the risk of developing cirrhosis-related complications, delaying the onset of hepatocellular carcinoma, and improving survival. Furthermore, the study aims to evaluate their impact on parents' related quality of life.

Official title: The Potential Role of Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis: A Quadruple Blind Clinical Study

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2022-11-15

Completion Date

2026-01-25

Last Updated

2026-08-11

Healthy Volunteers

No

Interventions

DRUG

Allopurinol 300 MG

a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation

DRUG

Atorvastatin 20mg

is lipid-lowering agent with anti-oxidative stress and anti-inflammation properties

DRUG

Placebo

not containing drugs

Locations (1)

Tanta University

Tanta, Egypt